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Abstract
Capsular switching allows pre-existing clones of Streptococcus pneumoniae expressing
vaccine serotypes to escape the vaccine-induced immunity by acquisition of capsular
genes from pneumococci of a non-vaccine serotype. Here, we have analysed the clonal
composition of 492 clinical isolates of serotype 11A causing invasive disease in Spain
(2000–2012), and their ability to evade the host immune response. Antibiograms, serotyp-
ing and molecular typing were performed. The restriction profiles of pbp2x, pbp1a and
pbp2b genes were also analysed. Interaction with the complement components C1q, C3b,
C4BP, and factor H was explored whereas opsonophagocytosis assays were performed
using a human cell line differentiated to neutrophils. Biofilm formation and the polymor-
phisms of the major autolysin LytA were evaluated. The main genotypes of the 11A pneu-
mococci were: ST62 (447 isolates, 90.6%), followed by ST6521 (35 isolates, 7.3%) and
ST838 (10 isolates, 2.1%). Beta lactam resistant serotype 11A variants of genotypes
ST838 and ST6521 closely related to the Spain9V-ST156 clone were first detected in 2005.
A different pattern of evasion of complement immunity and phagocytosis was observed
between genotypes. The emergence of one vaccine escape variant of Spain9V-ST156
(ST652111A), showing a high potential to avoid the host immune response, was observed.
In addition, isolates of ST652111A showed higher ability to produce biofilms than ST83811A
or ST6211A, which may have contributed to the emergence of this PEN-resistant ST652111A
genotype in the last few years. The emergence of penicillin-resistant 11A invasive variants
of the highly successful ST156 clonal complex merits close monitoring.
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Introduction
Streptococcus pneumoniae is the most common etiologic agent of acute otitis media, commu-
nity-acquired pneumonia, non-epidemic meningitis and a major cause of bacterial sepsis, espe-
cially in young children and older adults [1,2]. The capsule is considered the main
pneumococcal virulence factor and, up to 96 distinct capsular polysaccharides (CPS) have been
described [3]. Pneumococci of various serotypes, such as 1 and 7F, show low genetic diversity,
whereas serotype 19A CPS is expressed by several genotypes that show geographical and tem-
poral variations [4–6]. Exchange of capsular synthetic loci between pneumococcal strains (cap-
sular switching) provides a mechanism of immune-escape to PCV7 serotype clones [7–9].
Invasive pneumococcal disease (IPD) is a complex process in which several factors are
involved, including the virulence of the infective strain and the host immune response. Recog-
nition and clearance by the complement system and phagocytic cells is critical to prevent the
development of IPD [10,11]. Complement activation leads to the formation of the key comple-
ment component C3b that plays a major role in innate and adaptive immunity to pneumococ-
cus [12]. Among the three complement cascades, the classical pathway (CP) has been shown to
be essential against S. pneumoniae [13,14]. Establishment of IPD is preceded by nasopharyn-
geal colonization where the bacterium is located as a sessile microbial community avoiding
complement immunity and phagocytosis by inducing biofilm formation [15]. The reasons
underlying the different colonizing capacities observed between pneumococcal strains are
unclear, although the chemical composition and structure of the CPS may play roles [16]. An
additional threat for the outcome of the infection, is the emergence of clinical isolates with high
levels of antibiotic resistance [4,6,7,17–20]. In pneumococci, resistance to β-lactam antibiotics
is due to modified penicillin-binding proteins (PBPs), mainly PBP1A, PBP2B and PBP2X,
which reduce the affinity for these antibiotics [21]. Both pbp1a and pbp2x genes are located
flanking the capsular locus, and in some cases, the recombination fragment also includes par-
tial or intact pbp1a and pbp2x genes, leading to the acquisition of a new CPS together with new
PBP genes [20].
Over the last three decades, invasive serotype 11A pneumococci received at the Spanish
Pneumococcal Reference Laboratory (SPRL) were usually penicillin-susceptible. However,
since 2005, emergence of penicillin-resistant serotype 11A pneumococci has been identified
resulting in a significant concern as this serotype is not included in the current conjugate vac-
cines. Our study shows that certain genotypes within serotype 11A, might have an evolutionary
advantage to persist and spread in the future because they more efficiently avoid the host
immune response, which may explain the emergence of this serotype in recent years.
Materials and Methods
Ethics statement
Healthy subjects gave their written informed consent prior to the collection of their serum. The
Instituto de Salud Carlos III Ethic Committee approved this study (Approval Reference: PA
52_2011-v2).
Bacterial isolates, susceptibility testing and growth conditions
The study included all pneumococcal invasive isolates (n = 26124) received at the SPRL during
the period 2000–2012 from 190 Spanish hospitals located all over the country. Susceptibility to
penicillin (PEN), amoxicillin (AMX) and cefotaxime/ceftriaxone (CTX/CRO) was determined
as previously described [22]. S. pneumoniae strains selected for immunological studies were
cultured on blood agar plates at 37°C in a CO2 atmosphere, or in Todd-Hewitt broth
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supplemented with 0.5% yeast extract, to an optical density at 550 nm (OD550) of 0.5. Stocks
were stored at -70°C in 10% glycerol as single use aliquots for further experiments.
Serotyping and molecular typing
Isolates were serotyped by the Quellung reaction, dot blot assay [23] and/or real-time PCR [24]
whereas molecular characterization was performed by PFGE and MLST [20,25]. Since serotype
11A in Spain has been associated with the fully β-lactam-susceptible clone ST62, we performed
a randomized selection of 70 susceptible isolates using PFGE/MLST analysis, in order to con-
firm their genotype. In addition, all serotype 11A pneumococci with a decreased susceptibility
to β-lactams (n = 45), were genotyped by PFGE. Since all PEN-resistant pneumococci shared
an identical PFGE pattern, five selected isolates were subjected to MLST. The remaining PEN-
resistant isolates were chosen for aroE and ddl sequencing, since ST838 and ST6521 each differ
from ST156 within one or both of these MLST targets.
PBPs fingerprinting
The restriction fragment length polymorphism (RFLP) profiles of pbp1A, pbp2X and pbp2B of
β-lactam-resistant 11A pneumococci were analysed as previously described [20]. The PBP gene
RFLP patterns from the β-lactam-resistant 11A pneumococcal isolates were visually compared
with those of the control strains ATCC 700671 (Spain9V-ST156) and clinical isolate
HUB10926 (11A/ST62). In addition, at least two isolates belonging to each ST were selected for
PBP-sequencing [20].
Complement factors binding to S. pneumoniae
Fifteen invasive clinical isolates of serotype 11A (five of each ST62, ST838 and ST6521) were
selected to evaluate their interaction with complement factors. C1q, C3b, FH and C4BP deposi-
tion were analyzed using a flow cytometry assay as previously described [14,15,26]. The results
were expressed as a relative % fluorescence index (RFI) that measures not only the proportion
of fluorescent bacteria positive for the host serum component investigated but also the inten-
sity of fluorescence that quantify the amount bound [26,27].
Opsonophagocytosis assays
Experiments investigating phagocytosis were performed using a flow cytometry assay including
S. pneumoniae labeled with 5, 6-carboxyfluorescein succinimidyl ester (FAM-SE; Molecular
Probes) and human HL-60 cells (CCL-240; ATCC) differentiated to granulocytes
[14,15,27,28]. Infection assays were performed with a ratio of 10 bacteria per cell. Results were
expressed as a RFI defined as the proportion of positive cells for fluorescent bacteria multiplied
by the geometric mean of fluorescence intensity, which correlates with the amount of bacteria
phagocytosed per cell [26,27].
Biofilm quantification
Biofilm formation was determined as the ability of pneumococcal cells to adhere to the walls
and base of 96-well polystyrene microtiter plates (Costar 3595; Corning) as previously
described [15,29]. After 6 h of incubation at 34°C, the biofilm formed was stained with 0.2%
crystal violet and rinsed to remove non-adherent bacteria. After solubilizing the biofilm in 95%
ethanol (200 μl per well), OD595 was determined using a microplate reader (Anthos 2020).
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Confocal microscopy
HL-60 cells were infected with FAM-SE labeled pneumococcal strains as described before [26].
DNA was stained with Hoechst (Invitrogen) whereas actin cytoskeleton was stained with rho-
damine-phalloidin (Invitrogen) [26]. Phagocytosis was analyzed with a Leica spectral SP5 con-
focal microscope using the Leica software (LAS-AF). Biofilm formation was observed using a
Leica TCS-SP2-AOBS-UV confocal microscope. Briefly, pneumococcal isolates were grown on
glass-bottom dishes (WillCo-dish, WillCo Wells) for 6 h at 34°C and stained with the BacLight
kit showing living (green fluorescence) and dead (red fluorescence) bacteria, as previously
described [29].
Statistical analysis
Data are representative of results obtained from at least three repeated independent experi-
ments, and each data point represents the mean and standard deviations (SD) for 3 to 5 repli-
cates. Statistical analysis was performed by using two-tailed Student’s t test (for two groups),
whereas analysis of variance (ANOVA) followed by a Dunnett post hoc test were chosen for
multiple comparisons. GraphPad InStat version 5.0 (GraphPad Software, San Diego, CA) was
used for statistical analysis. Differences were considered statistically significant with P< 0.05
() and highly significant with P< 0.01 () or P< 0.001 ().
Results
Trends in epidemiology of pneumococcal serotype 11A
A total of 492 invasive isolates (1.9%) of 26124 invasive pneumococci sent to the SPRL from
2000 to 2012 expressed serotype 11A. Of them, 451 were isolated from adult patients (1.7% of
overall adult IPD) and 31 isolates were obtained from children (0.1% of children IPD). Fig 1a
shows the trends in frequency of serotype 11A among invasive pneumococci from children
and adults in Spain. Serotype 11A was isolated more frequently among adults (P<0.001).
Overall, the proportion of serotype 11A among invasive pneumococci increased from 1.3% in
2000 (13 isolates) to 3.3% in 2012 (67 isolates) (P<0.01). In the last three years, coinciding
with the introduction of PCV-13 in Spain, the increase of serotype 11A was also significant
from 2.1% in 2010 (46 isolates) to 3.3% in 2012 (67 isolates) (P<0.05) (Fig 1A). Although our
data shows an increase in the proportion of serotype 11A IPD, this increase was modest, with a
peak of 3.3% of total IPD in 2012. All invasive isolates of serotype 11A collected from 2000 to
2004, were susceptible to PEN (MIC0.06 μg/ml), CTX/CRO (MIC0.06 μg/ml) and AMX
(MIC0.06 μg/ml). In 2005 highly penicillin-resistant (MIC> 2 μg/ml) serotype 11A isolates
were detected (Fig 1B). These isolates markedly increased during 2010–2012, reaching a pro-
portion of 23.8% of 11A IPD isolates recovered during 2012 (15 PEN-resistant isolates vs 48
PEN-susceptible isolates) (Fig 1B) (P<0.001).
Molecular characterization. All PEN-susceptible serotype 11A pneumococci belonged to
the same PFGE cluster and were related to ST62. The molecular characterization of PEN-resis-
tant serotype 11A isolates demonstrated the existence of two genotypes: ST652111A (n = 35;
7.3%) and ST83811A (n = 10; 2.1%). ST83811A was first detected in 2005 but with its peak dur-
ing 2009 and 2010 (Fig 1B). In contrast, ST652111A was detected during 2009, increasing to
31% in 2011 (Fig 1B). Currently ST652111A is the predominant PEN-resistant clone in children
and adults (Fig 1B). Both ST83811A and ST652111A are closely related to ST156, which origi-
nated in the highly successful Spain9V-ST156 clone (Table 1). ST652111A is a single locus vari-
ant (SLV) of ST838 and a double locus variant (DLV) of ST156; ST83811A is a SLV of ST156
(Table 1). In terms of penicillin resistance, we have seen an increase of PEN-resistant IPD
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Fig 1. Epidemiology of serotype 11A pneumococci in Spain. (A) Invasive serotype 11A isolate recovery
over time from children and adults in Spain (2000–2012). (B) Distribution of serotype 11A genotypes over the
study period. PEN-R (penicillin-resistant MIC2μg/ml), PEN-S (penicillin susceptible MIC0.06 μg/ml). All
PEN-R isolates were genotyped whereas only 70 PEN-S serotype 11A isolates were subjected to MLST
analysis.
doi:10.1371/journal.pone.0137565.g001
Table 1. Characteristics of Major Genotypes of Serotype 11A and Spain9V-ST156 Clone.
β-lactam MIC (μg/ml)b
Sequence Type MLST allelesa PEN CTX AMX PBP1A/2B/2X
allelec
ST62d 2 5 29 12 16 3 14 0.06 0.06 0.5 A A A
ST156e 7 11 10 1 6 8 1 2 1 2 B B B
ST838f 7 11 10 1 6 8 90 2–4 1–2 4–16 B C B
ST6521f 8 11 10 1 6 8 90 1–4 0.5–2 4–16 B C B
aaroE, gdh, gki, spi, recP, xpt, ddl alleles.
bPEN, penicillin (susceptible: MIC 0.06 μg/ml, CLSI meningitis criteria); CTX-CRO, cefotaxime-ceftriaxone (susceptible: MIC 1 μg/ml, CLSI non-
meningitis criteria); AMOX, amoxicillin (susceptible: MIC 2 μg/ml, CLSI non-meningitis criteria).
cCapital letters were used to deﬁne different alleles of each PBP.
dOnly 70 Pen-S isolates were typed.
eATCC 700671 used as representative isolate of this genotype. No ST156 pneumococci expressing serotype11A were detected in the present study.
fAll Pen-R isolates were typed.
doi:10.1371/journal.pone.0137565.t001
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isolates of serotype 11A from 1 isolate in 2008 (0.7% of total PEN-R IPD isolates) to 14 isolates
in 2012 (10% of total PEN-R IPD isolates). The number of PEN-R 11A during 2012 was only
exceeded by serotype 14 (35%) and serotype 19A (38.3%).
PBP fingerprinting. All ST 838 and ST6521 isolates shared identical PCR-RFLP profiles
and DNA sequences for pbp1a, pbp2b and pbp2x, associated with similar β-lactam MICs (PEN,
2–4 μg/ml; CTX 1–2μg/ml; AMX 4–8 μg/ml). The two PEN-R 11A strains shared the same
pbp1a and pbp2x RFLP profiles with ATCC 700671 (9V-ST156). These three resistant strains
shared identical pbp1a sequences and closely related pbp2x (5 amino acid substitutions not pre-
dicted to affect resistance). There were 21 residues that differed between the pbp2b of the two
PEN-R 11A strains compared to ATCC 700671, again at positions not predicted to be associ-
ated with ß-lactam resistance.
Differential recognition of 11A clones by the complement system
The successful emergence of certain pneumococcal clones could be linked to increased effi-
ciency in avoiding the host immune system. The more successful emergence of ST652111A rela-
tive to ST83811A might be in part due to avoidance of C1q and C3b deposition (Fig 2).
Although less effective in this regard than the prevalent ST6211A, within the ST652111A genetic
background these results potentially reflect an evolutionary advantage in escaping the comple-
ment system (Fig 2).
Recruitment of fluid phase down-regulators such as C4BP and FH by microbial pathogens
reduces the activation of the CP or alternative pathway respectively [30]. Binding to C4BP but
not to FH was increased in isolates belonging to ST6211A and ST652111A compared to
ST83811A, potentially associating the reduced opsonization by C1q and C3b with enhanced
C4BP recruitment (Fig 3).
Opsonophagocytosis of serotype 11A
To investigate the interaction of the three different genotypes with human neutrophils, an
opsonophagocytosis assay was performed. Our findings indicated that invasive clinical isolates
of ST6211A are more resistant to phagocytosis than those of ST652111A and ST83811A (Fig 4).
Among PEN-resistant genotypes, isolates of ST652111A have a higher ability to divert pneumo-
coccal phagocytosis than isolates of ST83811A (Fig 4).
In vitro biofilm formation by serotype 11A IPD isolates
We investigated in vitro biofilm formation by 11A IPSD isolates with the pneumococcal R6
strain included as reference control. The biofilm forming capacity of invasive clinical isolates of
serotype 11A was lower than that of the R6 strain probably due to differences in capsule expres-
sion, as the R6 strain is a non-encapsulated strain (Fig 5). Isolates of ST652111A showed a
higher ability to produce biofilms than ST83811A or ST6211A (Fig 5).
Discussion
Although pneumococcal conjugate vaccines are a proven success against targeted serotypes,
considerable disease is also caused by certain non-vaccine serotypes which showed increased
disease association in recent years [1,31–34]. One example was the emergence of the multi-
drug resistant clone CC320 expressing serotype 19A, which was disseminated worldwide
shortly after PCV-7 implementation, causing IPD in children and adults [5]. Our study shows
some increased proportion of IPD caused by serotype 11A pneumococcal strains, especially in
adult patients. The timing of this increased proportion coincides in time with the introduction
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of broader conjugate vaccines in Spain (PCV-10 and PCV-13). The proportion of serotype 11A
associated with non-invasive pneumococcal disease has also increased in Spain during the
period 2000–2012 (from 3.3% to 9.3% for adults (P<0.001) and from 0% to 10.8% in children
(P<0.01) (data not shown). It is very important to closely monitor serotypes such as 11A that
are already associated with a significant proportion of post-PCV pneumococcal disease and
have unknown future potentials to cause greater disease burdens. Molecular characterization
revealed the existence of three different genotypes, the well-known β-lactam susceptible clone
ST6211A, and two PEN- and AMX-resistant emerging clones, ST83811A and ST652111A. Both
β-lactam-resistant genotypes are variants of Spain9V-ST156 clone, which has been one of the
most successful pneumococcal clones disseminated worldwide before PCV-7 introduction
[5,32,35–37]. Serotype 11A variants of the ST156 clonal complex clone were described previ-
ously in Israel [32]. Since the 1980s in Spain, strains of this clonal complex have typically been
associated with serotypes 9V and 14 (both included in current PCVs). Among adults, these
strains caused the highest proportion (11.6%) of IPD [6]. The emergence of penicillin-non-sus-
ceptible serotype 11A strains of the highly successful ST156 lineage is of concern. These strains
are not targeted by vaccines, and the majority of these isolates were AMX-resistant following
non-meningitis criteria, which could preclude the use of this antibiotic in the treatment of
Fig 2. Recognition of the different genotypes within serotype 11A by the complement system. (A)
Deposition of the first component C1q of the classical pathway on the surface of the different isolates. (B)
Example of a flow cytometry histogram for C1q deposition. (C) C3b deposition on the surface of strains of the
different genotypes. (D) Example of a flow cytometry histogram for C3b deposition. Error bars represent the
standard deviations (SDs) and asterisks indicate statistical significance between the different genotypes. For
the comparison between isolates of genotypes ST6211A and ST652111A compared to ST83811A, P < 0.001
(one-way ANOVA with Dunnett’s post hoc test).
doi:10.1371/journal.pone.0137565.g002
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pneumococcal disease in the community. The ST838 genotype associated with AMX-resistance
was first described among serotype 9V isolates in the late 1990s [33,38], and is the putative
ancestor of the 11A-ST838 variant. Although the ST6521 and ST838 variants differ in MLST
genotype at only one locus, their different behaviors in reaction to the human immune
response suggest additional genomic differences [8]. Our results suggest that the ST83811A
served as an intermediate strain that may have accumulated additional selectively advanta-
geous changes during its conversion to ST652111A.
Innate and adaptive immunity are critical factors for host defense during IPD, and clearance
of pneumococci from the bloodstream is greatly dependent on opsonization by complement
components and phagocytosis [10,11]. Clinical isolates of the ST6211A clone showed an increased
ability to avoid CP activation relative to the resistant 11A strains described in this study by target-
ing C1q and C4BP, leading to an impaired recognition by the key complement component C3b.
This is of great relevance because the CP is the dominant pathway in complement activation and
phagocytosis of S. pneumoniae [13,14]. Of the two PEN-resistant 11A clones, ST652111A avoided
the immune response more efficiently than isolates of ST83811A. Although the numbers of iso-
lates investigated are small, the observed difference in interaction with the CP might explain the
increased incidence of ST652111A in IPD relative to ST83811A. This is important because a clear
correlation exists between resistance to phagocytosis and carriage, where isolates more resistant
to neutrophil clearance have an advantage to persist in the nasopharynx [7].
Fig 3. Recruitment of complement down-regulators C4BP and factor H by the different genotypes of
serotype 11A. (A) C4BP binding to the surface of the different isolates. (B) Example of a flow cytometry
histogram for C4BP deposition. (C) Recruitment of factor H on the surface of the different genotypes. (D)
Example of a flow cytometry histogram for factor H deposition. Error bars represent the standard deviations
(SDs) and asterisks indicate statistical significance between the different genotypes.
doi:10.1371/journal.pone.0137565.g003
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Antibiotic resistance is likely to provide a selective advantage in the nasopharyngeal reser-
voir, assuming that this advantage outweighs imposed fitness cost [39]. Biofilm formation pro-
vides an advantage during nasopharyngeal colonization or during the early steps of cellular
attachment for dissemination, providing a mechanism for the avoidance of the immune
response and reducing exposure to antibiotics [15,40]. The ability of pneumococcal serotypes
to form biofilm could be used to predict the expansion of non-vaccine serotypes [16,41]. Inva-
sive strain of ST652111A showed a higher capacity to form biofilms than strains of ST83811A
and ST6211A, which has possibly contributed to the emergence of this clone in the last few
years. It is also possible that variation in capsule expression lead to some of these differences.
Fig 4. Opsonophagocytosis by HL-60 cells differentiated to human neutrophils. (A)
Opsonophagocytosis of the different genotypes within serotype 11A by flow cytometry. (B) Example of a flow
cytometry histogram for phagocytosis. (C) Opsonophagocytosis of the different isolates fluorescently labeled
with FAM-SE detected by confocal microscopy. DNA was stained by Hoechst, actin cytoskeleton was
visualized with Rhodamine-Phalloidin (RRX) staining and bacterial isolates of the different genotypes were
fluorescently labeled with FAM-SE. Error bars represent the standard deviations (SDs) and asterisks indicate
statistical significance between the different genotypes. For the comparison between isolates of genotypes
ST6211A and ST652111A compared to ST83811A, p < 0.001 (one-way ANOVAwith Dunnett’s post hoc test).
doi:10.1371/journal.pone.0137565.g004
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For example, differences in capsule expression at different stages of biofilm formation could
affect this process. It should be noted that under the conditions used for serotyping, the strains
appeared qualitatively similar in expression of capsule. There is considerable accumulated data
that indicates that features besides CPS expression modulate biofilm formation and interac-
tions with complement-mediated immunity [16,29,41,42].
Continued strain surveillance studies and characterization of emergent disease-causing
strains is necessary in order to gain a better understanding of what features lead to the success
of individual successful pneumococcal clones.
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